Short radiation and drug combo for advanced rectal cancer
Part of Cancer clinical trials.
This trial tests a combination of short-course radiation, chemotherapy, and two types of targeted drugs to shrink metastatic rectal cancer that cannot be removed by surgery. The goal is to help reduce the cancer and possibly make it operable later.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have rectal cancer that has just been diagnosed and has not been treated with surgery, radiation, or drugs before.
- Your cancer has spread to other parts of the body, like the liver or lungs.
- You need to provide a tissue sample (from a biopsy) so the study team can check special markers on your cancer cells.
- You have normal blood, heart, liver, and kidney function, and you are physically active (able to do light work).
- You have not taken immune-boosting drugs (like PD-1 or PD-L1 inhibitors) in the past.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
This trial tests whether adding radiation therapy to a combination of chemotherapy (CAPOX) and an immunotherapy drug (PD-1 antibody) is more effective than the combination alone for people with locally advanced rectal cancer that is MSS (microsatellite stable) or pMMR. It aims to improve outcomes for patients with high-risk features.
This trial tests a new combination for locally advanced rectal cancer: adding a cholesterol-lowering drug plus an immunotherapy drug to the standard chemotherapy and radiation before surgery. The goal is to see if this combination shrinks tumors more effectively and improves outcomes.
This trial tests a new approach for locally advanced rectal cancer. You'll receive a short course of radiation, then chemotherapy plus an immunotherapy drug (a PD-1 inhibitor). The goal is to see if this combination shrinks the tumor enough to avoid surgery or improve outcomes.
This trial tests a short course of radiation therapy followed by a combination of three drugs (fruquintinib, adebrelimab, and CAPOX chemotherapy) before surgery for people with locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether combining short-course radiation with a chemotherapy regimen (CAPOX) and an immunotherapy drug (QL1706) can help treat rectal cancer that has spread to the liver. It is designed for patients who have not had any prior cancer treatment.
Hear when a new Unresectable Metastatic Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.